Today: 11 June 2026
Citigroup stock hits fresh 52-week high as Barclays lifts target ahead of earnings
6 January 2026
1 min read

Citigroup stock hits fresh 52-week high as Barclays lifts target ahead of earnings

New York, January 5, 2026, 19:21 ET — After-hours

  • Citigroup shares closed up nearly 4% at a new 52-week high as bank stocks led Wall Street higher.
  • Barclays lifted its Citi price target as analysts recalibrated big-bank outlooks for 2026.
  • Traders now eye U.S. jobs and inflation data before Citi reports quarterly results next week.

Citigroup Inc (C.N) shares rose 3.9% to close at $123.30 on Monday and were last little changed in after-hours trading. The move set a new 52-week high, topping the prior peak of $122.84 set on Dec. 24. JPMorgan Chase (JPM.N) gained 2.6%, Bank of America (BAC.N) rose 1.7% and Wells Fargo (WFC.N) added 1.2%, while Citi’s trading volume of 17.8 million shares topped its 50-day average of 12.4 million.

The bank’s push to a fresh high comes as investors rotate toward financials ahead of a busy stretch of quarterly reports. For Citi, the rally raises the stakes for any update on margins, credit trends and cost discipline.

The S&P 500 financials index jumped 2.2% on Monday, and analysts on average expect financial companies in the index to grow earnings 6.7% from a year earlier in the December quarter. “The mood has been favoring financial stocks in recent days,” said Steve Sosnick, chief market analyst at Interactive Brokers. Wall Street’s broader rally was helped by a risk-on shift after a U.S. military strike captured Venezuelan President Nicolas Maduro, while markets are pricing about 60 basis points of Federal Reserve easing this year, according to LSEG — a basis point is one hundredth of a percentage point. reuters.com

Analyst calls also turned more supportive. Barclays analyst Jason Goldberg raised the firm’s price target on Citi to $146 from $115 and kept an “Overweight” rating — a call that the stock should outperform its sector — according to TheFly. tipranks.com

Citi said it will release fourth-quarter results at about 8 a.m. ET on Wednesday, Jan. 14, followed by a webcast and conference call at 11 a.m. ET.

Investors will be listening for detail on net interest income — the gap between what a bank earns on loans and pays on deposits — as rate expectations shift and competition for deposits stays in focus. They will also be watching credit-loss provisions, investment-banking fee trends and any signal on capital returns.

Rate-cut bets are a double-edged driver for big banks. They can narrow lending spreads over time, but they can also lower funding costs and influence markets activity and dealmaking, which feed into trading and advisory revenue.

But the rally leaves less room for disappointment. Any sign of softer loan demand, a turn in consumer credit performance, or a stickier expense base could trigger profit-taking after the run to a new high.

Next up is Friday’s U.S. nonfarm payrolls report (Jan. 9), followed by the December consumer price index on Jan. 13, before Citi’s earnings on Jan. 14.

Stock Market Today

  • TIG Advisors Reduces Stake in Beazley PLC by 330,000 Shares
    June 11, 2026, 10:47 AM EDT. TIG Advisors, LLC, acting as discretionary investment manager for AlTi Global, Inc., disclosed a reduction in its long position in Beazley PLC's shares. After the deal on June 10, 2026, it held 5,928,546 derivative shares, representing 0.99% of Beazley's total securities (ISIN: GB00BYQ0JC66). The transaction involved selling 330,000 5p ordinary shares at a price of 1,283.00 pence per unit. The disclosure was made under Rule 8.3 of the UK's Takeover Code, which requires revealing interests exceeding 1% in relevant securities. This transaction signals a strategic portfolio adjustment by TIG Advisors in the insurance firm's equity.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Why MercadoLibre (MELI) stock jumped nearly 9% on Venezuela shock headlines
Previous Story

Why MercadoLibre (MELI) stock jumped nearly 9% on Venezuela shock headlines

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms
Next Story

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms

Go toTop